Supramolecular PEGylation of biopharmaceuticals

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 50, 2016, Pages 14189-14194

  Webber, Matthew J ^a,b   Appel, Eric A ^a   Vinciguerra, Brittany ^c   Cortinas, Abel B ^d   Thapa, Lavanya S ^a,b   Jhunjhunwala, Siddharth ^a   Isaacs, Lyle ^c   Langer, Robert ^a,b,d   Anderson, Daniel G ^a,b,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c University of Maryland   (United States)

^d Massachusetts Institute of Technology   (United States)

Author keywords

Drug delivery; Protein engineering; Protein formulation; Supramolecular chemistry

Indexed keywords

GLUCOSE; PROTEIN KINASE B; RECOMBINANT HUMAN INSULIN; BRIDGED COMPOUND; CUCURBIT(7)URIL; IMIDAZOLE DERIVATIVE; INSULIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; BINDING AFFINITY; CHEMICAL MODIFICATION; COMPLEX FORMATION; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; COVALENT BOND; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG FORMULATION; DRUG STABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PEGYLATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SUPRAMOLECULAR CHEMISTRY; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; CLICK CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; MOLECULAR MODEL; PHARMACEUTICS; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; BIOPHARMACEUTICS; BRIDGED-RING COMPOUNDS; CELL LINE; CLICK CHEMISTRY; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMIDAZOLES; INSULIN; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; POLYETHYLENE GLYCOLS; PROTEIN ENGINEERING; PROTEIN STABILITY; RECOMBINANT PROTEINS;

EID: 85006065001     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1616639113     Document Type: Article

References (46)

1. Aggarwal RS (2014) What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 32(1):32-39.
2. Shire SJ, Shahrokh Z, Liu J (2004) Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-1402.
3. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21(6):897-903.
4. Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185(2):129-188.
5. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB (2011) Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63(13):1118-1159.
6. Keefe AJ, Jiang S (2011) Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat Chem 4(1):59-63.
7. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6(9):688-701.
8. Kurtzhals P, et al. (1995) Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312(Pt 3):725-731.
9. Alconcel SNS, Baas AS, Maynard HD (2011) FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym Chem-Uk 2(7):1442-1448.
10. Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54(4):459-476.
11. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2(3):214-221.
12. Jevsevar S, Kunstelj M, Porekar VG (2010) PEGylation of therapeutic proteins. Biotechnol J 5(1):113-128.
13. Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10(21):1451-1458.
14. Webber MJ, Appel EA, Meijer EW, Langer R (2016) Supramolecular biomaterials. Nat Mater 15(1):13-26.
15. Schneider HJ (1991) Mechanisms of molecular recognition-investigations of organic host guest complexes. Angew Chem Int Ed Engl 30(11):1417-1436.
16. Davis ME, Brewster ME (2004) Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discov 3(12):1023-1035.
17. Uekama K, Otagiri M (1987) Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Syst 3(1):1-40.
18. Cao L, et al. (2014) Cucurbit[7]uril·guest pair with an attomolar dissociation constant. Angew Chem Int Ed Engl 53(4):988-993.
19. Urbach AR, Ramalingam V (2011) Molecular recognition of amino acids, peptides, and proteins by cucurbit[n]uril receptors. Isr J Chem 51(5-6):664-678.
20. Ma X, Zhao Y (2015) Biomedical applications of supramolecular systems based on host-guest interactions. Chem Rev 115(15):7794-7839.
21. Rekharsky MV, et al. (2007) A synthetic host-guest system achieves avidin-biotin affinity by overcoming enthalpy-entropy compensation. Proc Natl Acad Sci USA 104(52): 20737-20742.
22. Moghaddam S, et al. (2011) New ultrahigh affinity host-guest complexes of cucurbit [7]uril with bicyclo[2.2.2]octane and adamantane guests: Thermodynamic analysis and evaluation of M2 affinity calculations. J Am Chem Soc 133(10):3570-3581.
23. Lee DW, et al. (2011) Supramolecular fishing for plasma membrane proteins using an ultrastable synthetic host-guest binding pair. Nat Chem 3(2):154-159.
24. Liu S, et al. (2005) The cucurbit[n]uril family: Prime components for self-sorting systems. J Am Chem Soc 127(45):15959-15967.
25. Kim K, et al. (2007) Functionalized cucurbiturils and their applications. Chem Soc Rev 36(2):267-279.
26. Lee JW, Samal S, Selvapalam N, Kim HJ, Kim K (2003) Cucurbituril homologues and derivatives: New opportunities in supramolecular chemistry. Acc Chem Res 36(8):621-630.
27. Vinciguerra B, et al. (2012) Synthesis and self-assembly processes of monofunctionalized cucurbit[7]uril. J Am ChemSoc 134(31):13133-13140.
28. Ahn Y, Jang Y, Selvapalam N, Yun G, Kim K (2013) Supramolecular Velcro for reversible underwater adhesion. Angew Chem Int Ed Engl 52(11):3140-3144.
29. Cao L, Hettiarachchi G, Briken V, Isaacs L (2013) Cucurbit[7]uril containers for targeted delivery of oxaliplatin to cancer cells. Angew Chem Int Ed Engl 52(46):12033-12037.
30. Ayhan MM, et al. (2015) Comprehensive synthesis of monohydroxy-cucurbit[n]urils (n = 5, 6, 7, 8): High purity and high conversions. J Am Chem Soc 137(32):10238-10245.
31. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G; EURODIAB Study Group (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicentre prospective registration study. Lancet 373(9680):2027-2033.
32. Sluzky V, Tamada JA, Klibanov AM, Langer R (1991) Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci USA 88(21):9377-9381.
33. Hinds KD, Kim SW (2002) Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 54(4):505-530.
34. Chinai JM, et al. (2011) Molecular recognition of insulin by a synthetic receptor. J Am Chem Soc 133(23):8810-8813.
35. Onoue S, et al. (2004) Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res 21(7):1274-1283.
36. Castle JR, et al. (2010) Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 33(6):1282-1287.
37. Like AA, Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: New model of diabetes mellitus. Science 193(4251):415-417.
38. Chou DH, et al. (2015) Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc Natl Acad Sci USA 112(8):2401-2406.
39. Jockel JP, Roebrock P, Shergold OA (2013) Insulin depot formation in subcutaneous tissue. J Diabetes Sci Technol 7(1):227-237.
40. McLennan DN, Porter CJ, Charman SA (2005) Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol 2(1):89-96.
41. Swartz MA (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50(1-2):3-20.
42. Chertok B, Webber MJ, Succi MD, Langer R (2013) Drug delivery interfaces in the 21st century: From science fiction ideas to viable technologies. Mol Pharm 10(10):3531-3543.
43. Supersaxo A, Hein WR, Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7(2):167-169.
44. Veronese FM (2001) Peptide and protein PEGylation: A review of problems and solutions. Biomaterials 22(5):405-417.
45. Logsdon LA, Urbach AR (2013) Sequence-specific inhibition of a nonspecific protease. J Am Chem Soc 135(31):11414-11416.
46. Shaikh M, Mohanty J, Singh PK, Nau WM, Pal H (2008) Complexation of acridine orange by cucurbit[7]uril and beta-cyclodextrin: Photophysical effects and pKa shifts. Photochem Photobiol Sci 7(4):408-414.